CanniMed Therapeutics (TSX: CMED) priced its initial public offering at $12, selling 5mm shares through a syndicate led by AltaCorp Capital to raise $60mm. The underwriters, which also included Canaccord...

The list of Canadian licensed producers (LPs) of cannabis expecting to go public just got longer. CanniMed Therapeutics, the parent of CanniMed Ltd. and Prairie Plant Systems, issued a press...